COVID-19: Vaccines and Therapeutics
The Centers for Disease Control and Prevention reported 21 cases of anaphylaxis, a life-threatening allergic reaction, among the nearly 1.9 million people who received a first dose of the Pfizer COVID-19 vaccine between Dec. 14 and 23.
The Food and Drug Administration reminded the public of the importance of receiving COVID-19 vaccines in accordance to their agency authorizations, a process that FDA said will safely provide the “remarkable” levels of protection observed during large, randomized clinical trials.
To help advance the public’s confidence and trust in the safety of COVID-19 vaccines and their distribution, the AHA continues to develop and collate resources that hospitals and health systems can use as COVID-19 vaccines become available in their communities.
AHA comments on the Centers for Medicare & Medicaid Services’ hospital outpatient prospective payment system and ambulatory surgical center payment system final rule with comment period for calendar year 2021.
The COVID-19 Vaccine Communications Toolkit was developed as a guide through the steps involved in planning, designing and executing a vaccine communications plan and campaign.
At a Glance
House and Senate leaders late yesterday announced an agreement on a roughly $900 billion COVID-19 relief package that includes a number of provisions beneficial to hospitals and health systems. They also agreed on a roughly $1.4 trillion spending package that would fund the federal…
Centers for Medicare & Medicaid Services released updated guidance for states and territories on Medicaid, Children’s Health Insurance Program and Basic Health Program coverage and reimbursement for COVID-19 vaccinations.
The American Medical Association announced Current Procedural Terminology immunization and administration codes for reporting on medical claims the COVID-19 vaccine under development by AstraZeneca and University of Oxford.
The National Institutes of Health announced enrollment in phase 3 of the clinical trial of two disparate therapies. This trial is specifically looking at the safety and effectiveness of the therapeutics in people hospitalized with moderate COVID-19 symptoms.
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee Dec. 17 recommended the approval of Moderna’s mRNA-1273 COVID-19 vaccine candidate.